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What is already known on this topic?
 ► Intraventricular haemorrhages caused by rapid 
changes in blood pressure in neonates lead 
to adverse effects such as poor long-term 
neurodevelopment and increased mortality.
 ► Inotropes, commonly dopamine, are used in 
neonatal intensive care units (NICUs) to treat 
hypotension by increasing peripheral vascular 
resistance.
 ► Majority of studies that observed dopamine 
instability have used protocols with high 
temperature (>50°C).
What this study adds?
 ► Laboratory studies on dopamine instability 
under simulated NICU settings show rapid 
degradation within the first hour of the infusion, 
followed by gradual degradation over 24 hours.
 ► This coincides with a rapid fluctuation in mean 
arterial pressure (MAP) observed following 
infusion changeover of dopamine.
 ► Changing our standard operating procedure so 
that dopamine infusions were administered 30 
minutes after preparation and for a duration of 
12 hours removed rapid fluctuations observed 
in the MAP during infusion changeover.
AbsTrACT
Objective To evaluate whether changing dopamine 
infusions every 12 hours and preparing these infusions 
30 min before administration reduces blood pressure 
fluctuations in preterm and term neonates.
Design This was a retrospective study using data from 
live patients on the neonatal unit and prospective study 
exploring stability of infusions in a laboratory-based 
neonatal ward simulation.
setting Single-centre study in a tertiary neonatal 
surgical unit in a university teaching hospital.
Patients Neonates who received more than one 
subsequent dopamine infusion and had invasive arterial 
blood pressure monitoring, during their admission in the 
neonatal unit, were included.
Interventions As part of the Quality Improvement 
project, the standard operating procedure (SOP) was 
changed, and dopamine infusions were prepared 
by nursing staff and left to rest for 30 min before 
administering to the neonate. Additionally, infusions 
were replaced every 12 hours.
Main outcome measures The percentage change 
in mean arterial pressure (MAP) and the percentage 
loss in the drug concentration during infusion during 
changeover.
results Our findings indicate that up to 15% of the 
initial dopamine concentration is lost after 24 hours. 
This results in a sharp variation in the dopamine 
concentration during infusion changeover that correlates 
with observed rapid fluctuations in MAP. In changing 
the SOP, no significant difference in the concentration of 
dopamine and MAP were observed over 12 hours.
Conclusions Delaying administration of dopamine 
infusions by 30 min after preparation combined with 
changing infusions 12 hourly has reduced MAP 
fluctuations. Therefore, the risks associated with MAP 
fluctuations, including intraventricular haemorrhages, are 
reduced.
InTrODuCTIOn
Neonatal hypotension is a common condition with 
one-third to a half of neonates being hypotensive 
within 24 hours of admission to neonatal intensive 
care units (NICUs).1 This hypotension can be tran-
sient or persisting depending on its cause.2–4 Neonatal 
hypotension is initially treated with volume support 
followed by inotrope therapy (dopamine or dobu-
tamine) if blood pressure (BP) has not improved. 
The main goal of initiating inotrope therapy in a 
hypotensive neonate is to increase cardiac output 
and raise BP thereby maintaining adequate organ 
and tissue perfusion.5 6 Although inotrope therapy 
is widely used in neonatal hypotension, its efficacy 
in this patient population is often debated.7–10 At 
present, there is a lack of neonatal-specific formu-
lations and doses are prepared from adult vials. 
There are also observations of the fluctuations in BP 
following inotropic infusion changeover.11–14 It has 
been proposed that these fluctuations in BP can lead 
to poor organ perfusion, intraventricular haemor-
rhage (IVH), periventricular leucomalacia, retinop-
athy of prematurity and mortality.15 Additionally, 
IVH have been associated with poor neurological, 
motor and cognitive outcomes at both 1 and 2–3 
years of age.16 It is currently unclear whether the 
fluctuations arise as a result of therapy or hypoten-
sion2 4 7 17 but given the risks associated, it is crucial 
to minimise the fluctuations where possible.
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Figure 1 Changes in dopamine (DA) concentrations in a simulated 
neonatal ward laboratory setting. (A) The percentage of dopamine loss 
relative to changeover time, when prepared in varying dilution vehicles 
in the old standard operating procedure (SOP). (B) The percentage of 
dopamine loss relative to changeover time, when prepared in varying 
neonate weights in the old SOP. (C) The percentage of dopamine loss 
relative to changeover time, when prepared in varying dilution vehicles 
in the new SOP. (D) The percentage of dopamine loss relative to change 
over time, when prepared in varying neonate weights in the new SOP. 
Data shown as mean±95% CI, where *p<0.05.
The infusion changeover technique,14 18 knowledge and 
training of the nursing staff,19 and the stability of dopamine 
itself have been investigated as possible reasons for these BP 
fluctuations following infusion changeover. Little alteration in 
the frequency of rapid fluctuations in BP were observed when 
changeover technique and training of nursing staff were inves-
tigated as a cause. Stability studies have questioned dopamine’s 
stability when exposed to light, plastic, infusion vehicles and 
other drugs.20–27 Many of the stability studies conducted on 
dopamine were undertaken at room temperature and concluded 
dopamine to be stable. Stability was assumed at all temperatures, 
which led to dopamine being used in neonatal clinical practice. 
The doses used in these stability studies were often unrepresen-
tative of clinical dosing regimens; therefore, their conclusions 
cannot be applied to the neonatal population. The lack of data 
representative of the neonatal environment led to the study 
which assessed the role of light and infusion vehicles on dopa-
mine’s stability at 35°C, where a loss in stability was observed.20
In this retrospective and prospective study, we evaluated how 
the MAP varied during infusion changeover following imple-
mentation of a new standard operating procedure (SOP) for 
delivery of dopamine as part of the unit’s quality improvement 
project. This SOP was based on analysis of the changes in dopa-
mine concentration during infusion in neonatal simulated ward 
conditions.
MeThODs
Patient and public information
The parent’s forum group at the NICU was informed regarding 
the project proposed and consulted for their thoughts on the 
outcomes of our findings.
evaluation of dopamine concentration in laboratory-based 
neonatal simulated ward conditions
In the old SOP, infusions were administered for a maximum of 
24 hours. Based on the changes in dopamine stability observed, 
a new SOP was established to minimise changes in dopamine 
concentration, where infusions were prepared in syringes at 
room temperature, rested horizontally on a sterile field for 
30 min (except the first dose) prior to infusion for a maximum 
of 12 hours. The dopamine dose used to correct haemodynamic 
imbalance in neonates is initially 3 μg/kg/min with a maximum 
dose of 20 μg/kg/min.28 Therefore, the dosing regimens 
prepared were 0.6 mg/mL for neonatal weights of 1 kg (median 
weight seen in the NICU), 0.24 mg/mL for 400 g and 3 mg/mL 
for 5 kg (range of weights observed in the NICU). All doses were 
prepared by diluting vials of 200 mg/5 mL dopamine hydrochlo-
ride (Martindale Pharmaceuticals, Essex, UK) in 50 mL syringes 
in either 0.45% NaCl, 0.9% NaCl, 10% glucose or 5% glucose 
(Baxter Healthcare, Norfolk, UK). Infusions were placed into an 
incubator (Thermo Fisher Scientific) set at 35°C. Concentrations 
were analysed 30 min, 1 hour and 2 hours after the start of the 
infusion and 30 min and 1 hour before the end of the infusion 
for either SOP using high-performance liquid chromatography 
(method in online supplementary information).
Patient group and selection criteria
Our tertiary neonatal unit uses BadgerNet for daily online 
recording of all babies within neonatal services. Neonates of 
all gestations, weights and sexes that received more than one 
subsequent dopamine infusion during their admission into the 
unit and had their BP monitored invasively were selected in 
this retrospective and prospective study. Using BadgerNet, 13 
neonates meet the selection criteria who were on the old SOP 
and 17 neonates met the criteria for the new SOP (additional 
details on the patient group in online supplementary informa-
tion). In the neonatal unit, for the new SOP, following dilution 
of the dopamine by the nursing staff from the adult vial into 
the 50 mL syringe, the prepared dopamine was kept horizontally 
on a sterile field without being shaken, to avoid contamination. 
This was kept for 30 min before commencing administration.
Data collection and statistical analysis
MetaVision (a clinical information system for intensive care) 
captures all clinical observations on each neonate eligible to the 
study. Data on the birth weight, rate of the dopamine infusion 
in micrograms/kilogram/minute, total infusion duration, other 
infusions running at the same time including other inotropes, 
mean arterial pressure (MAP) 30 min and 1 hour preinfusion 
initiation and 30 min, 1 hour and 2 hours postinfusion initia-
tion were collected. The neonates under the old and new SOP 
were then compared. To measure dopamine concentration, the 
peak area from chromatography responses were obtained from 
identical sampling points as the MAP. Data were analysed using 
either a one-way or two-way analysis of variance (ANOVA) with 
post hoc Tukey tests, where significance was considered when 
p<0.05.
resulTs
Initially, the changes in dopamine concentration were measured 
through a laboratory setting simulated neonatal ward. 
Figure 1A,B shows changes when using the old SOP in various 
commonly used diluent vehicles and neonate weights. There 
was a significant change in the concentration of dopamine 
observed with time (p<0.05, two-way ANOVA) and a significant 
change in how this dopamine concentration altered in different 
diluent vehicles (p<0.05, n=10, figure 1A). At both −1 hour 
and −0.5 hour before changeover, the dopamine concentration 
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Figure 2 Difference between the new and old standard operating 
procedure in per cent of dopamine (DA) concentration loss from 
changeover when prepared in (A) 10% glucose, (B) 5% glucose, (C) 
0.9% sodium chloride and (D) 0.45% sodium chloride in the laboratory 
setting simulated neonatal ward. Data shown as mean±95% CI, where 
*p<0.05.
Figure 3 Representative traces of mean arterial pressures from 
neonates receiving dopamine (A) for 24 hours before infusion 
changeover (old standard operating procedure (SOP)) or (B) which was 
prepared 30 min prior to infusion and ran for 12 hours before infusion 
changeover (new SOP). The green line indicates the point where infusion 
changeover is conducted, and the red line indicates the mean arterial 
pressure (mm Hg) over time in hours.
was more stable in 0.45% NaCl when compared with 10% and 
5% glucose (p<0.05, n=10, Sidak test). When comparing the 
effect of dopamine stability on doses used for varying weights of 
neonates, there was a signficant increase in percentage of dopa-
mine lost with increased weight of the neonate (p<0.05, n=10, 
figure 2C). However, with neonatal weights ≤0.4 kg, there is 
no difference in the dopamine concentration during infusion 
changeover.
Due to the rapid loss in stability in the first 30 min followed by 
gradual loss in stability over 24 hours, the new SOP protocol was 
established to counteract these changes. No signficant difference 
in the percentage of dopamine concentration lost from initial 
concentration was observed in the varying diluent vehicles 
(figure 1C, n=10) or weight of the neonate (figure 1D, n=10).
When comparing the percentage loss in the concentration 
of dopamine measured from the laboratory setting simulated 
neonatal ward, in all diluent vehicles there was a significant 
difference between the two SOPs over the time sampled (p<0.05, 
figure 2). In all cases there was a signficant increase in the 
percentage of dopamine lost at −1 hour and −0.5 hour before 
changeover in the old SOP when compared with the new SOP 
(p<0.05, figure 2).
Figure 3A shows representative clinical traces spanning a 
12-hour period from three neonates who received dopamine infu-
sions for 24 hours. Clear presence of rapid BP fluctuations was 
observed postinfusion changeover. Figure 3B shows representa-
tive clinical traces over a 12-hour period from three neonates 
where dopamine infusions were administered for 12 hours after 
being prepared 30 min prior to infusion. No clear presence of 
rapid fluctuations was observed postinfusion changeover.
Evaluation of the changes in clinical MAP response, during 
changeover using the old and new SOPs, are shown in figure 4. 
There was a signficant increase in the MAP observed at 0.5 hour 
and 1 hour when compared with −0.5 hour and −1 hour in 
the old SOP (p<0.05, n=13 figure 4A). No signficant differ-
ences in the MAP were observed during changeover in the new 
SOP (figure 4A, n=17). When comparing the changes in MAP 
between the old and new SOPs, there was a significant difference 
between the two SOPs over the time sampled (p<0.05, two-way 
ANOVA, figure 4A). There was a signficant reduction in the MAP 
at −1 hour and −0.5 hour before infusion changeover in the old 
SOP when compared with the new SOP (p<0.05, figure 4A).
The number of times the dose was titrated up during an infu-
sion was compared, where a longer time was required for the 
first titrated dose (p<0.001, t test, figure 4B) and there was a 
decrease in the number of times the dose was titrated in the 
new SOP when compared with the old SOP (p<0.001, t test, 
figure 4C).
Figure 5A demonstrates the observed changes in the MAP and 
dopamine concentration (for a 1 kg neonate, prepared in 5% 
glucose diluent vehicle) during the infusion changeover using the 
old SOP. Figure 5B demonstrates the observed changes on the 
MAP and dopamine concentration (for a 1 kg neonate, prepared 
in 5% glucose diluent vehicle) during the infusion changeover 
in the new SOP. The green dashed line indicates when a drug 
concentration would be classed as unsuitable based on British 
Pharmacopoeia guidelines, in which dopamine concentration 
drop below this mark in the old SOP after 14 hours, while the 
response never drops below this point on the new SOP.
DIsCussIOn
Our study shows that by preparing dopamine 30 min prior to 
infusion and limiting the infusion duration to 12 hours, rapid 
fluctuations observed during infusion changeover in a 24-hour 
administration cycle are minimised. This new SOP is suitable 
for robust delivery of dopamine to neonates of all weights that 
may be treated for hypotension and for any dilution vehicle that 
dopamine is regularly prepared in for infusion.
This study supports previous observational studies that have 
identified rapid fluctuations in the MAP during infusion change-
over.5 9–11 29 Although many approaches to understand the effect 
observed at changeover have been taken, namely in evaluation 
and altering the practice of infusion changeover, these have 
yielded little improvement.14 18 19 The concentration of dopamine 
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Figure 4 Difference in the mean arterial pressure (MAP) between the 
new and old standard operating procedure (SOP). (A) The difference in 
the MAP. (B) The time following infusion changeover that the dose was 
required to be titrated and (C) the number of times the dose is titrated 
over 24 hours. Data shown as mean±95% CI, where *p<0.05 and 
***p<0.001 between SOPs, †p<0.05 on the old protocol when 
compared with −0.5 hour and −1 hour.
Figure 5 The changes in mean arterial pressure (MAP) and 
percentage of loss in dopamine (DA) concentration based over a 48-
hour period in the (A) old standard operating procedure (SOP) and (B) 
new SOP. The green line indicates the British Pharmacopoeia guidelines 
for medicines production which is >±7.5%. IC, infusion changeover.
during infusion has seldom been investigated as a cause and this 
study showcases the observed changes in dopamine concentra-
tion during infusion in a laboratory-simulated environment that 
replicates an infusion administered to a neonate within an incu-
bator in an intensive care unit. To date, only our previous study 
has shown that in a clinical environment dopamine stability 
varies,20 and this investigation adds further information covering 
a range of dilution vehicles and neonatal weights. These find-
ings provide significant insight into the impact of dose varia-
tion during infusion changeover when a 24-hour dosing cycle 
is used. Although many studies on dopamine stability have been 
conducted,21–23 26 27 they have negated to use appropriate doses 
used in a clinical environment, explore the influence of dilution 
vehicle and clinical environment conditions of delivery. Our 
study indicates these parameters play a key role in reducing the 
stability of dopamine gradually over 24 hours, which leads to a 
significant variation during changeover resulting in rapid fluctu-
ations in MAP.
Based on these observations, the guidelines by the British Phar-
macopoeia guidelines for medicines production indicate that 
any product that deviates >±7.5% from the drug dose would 
be classed as unsuitable30 and therefore based on figure 3, 12 
hours was defined as the safe timescale for dopamine infusions 
for the new SOP as the >±7.5% is breached at 14 hours as seen 
in figure 2D. Additionally, most of the dopamine degradation 
was observed in the first 2 hours, and therefore it was logical 
to prepare the infusion 30 min prior infusion. The resultant 
changes assured that at no point was the dopamine concentra-
tion in the new SOP outside the British Pharmacopoeia guide-
lines. Such changes to the new SOP also resulted in a reduction 
in the number of times the dose was titrated prior to change-
over and the time taken to the first time the dose was titrated 
following changeover.
Despite great efforts being made to simulate neonatal ward 
conditions as accurately as possible in a laboratory setting, there 
are a few experimental design limitations which can affect the 
interpretation of the data. These are highlighted in our previous 
publication and include the nature of the incubator used, which 
does not allow for maximal light, as used on the neonatal ward, 
therefore underestimating the degree of degradation.20 Another 
important consideration is that our study is a very simple clinical 
model that does not fully mimic drug delivery of inotropes, as 
often they are coadministered with other compounds, formula-
tions or parenteral nutrition. Additionally, other factors such as 
the type of infusion tubing and materials may also influence the 
degree of stability.
Within our study, we simulated the change in dopamine 
concentration as it was not possible to sample the infusion 
concentration at the varying timepoints within the clinical 
environment and match this directly with the change in MAP 
with the neonate. This type of matched observation would be 
of signficant advantage in understanding the context of dopa-
mine concentration difference needed for a rapid fluctuation to 
be observed. Additionally, we have not fully explored the causes 
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of dopamine’s instability; however, we have learned through 
previous studies that light is not a major cause of this degrada-
tion.20 Therefore, based on other studies and explored mecha-
nisms, other variables such as oxygen and heat exposure may 
explain this degradation.21 22
On surveying the hypotension guidelines from numerous 
NICU department within the UK (online supplementary table 
1), we obtained responses from one-third of NICUs. The data 
show all these NICUs currently administered immediately in 
a method that reflects the old SOP and therefore adoption of 
the new SOP can have significant impact in reducing the risk 
associated with rapid fluctuations during dopamine changeover. 
However, changing dopamine infusions every 12 hours can offer 
a signficant change to practice and requires the sterility of the 
infusion line to be broken twice as often.
This proposal only focused on understanding the changes 
in dopamine infusions; however, these represent only a small 
element of the hypotensive therapeutics provided and there-
fore further studies are needed to understand whether other 
inotropes are stable in neonatal ward conditions when either 
administered individually or in combination. Additionally, there 
is a host of varying conditions in which neonates are cared for 
within an intensive care unit. Our studies have focused solely 
on the stability of dopamine for neonates nursed within incu-
bators; however, we have not explored if similar effects occur 
when using an open cot, radiant warmer or cooling mattress. 
Finally, future studies need to account for all the variations in 
neonatal intensive care conditions in which phototherapy and 
humidity is also influenced. Both parameters have been shown in 
other studies to influence the stability of inotropes22 26 and there-
fore this would provide key insight on whether the new SOP can 
overcome rapid fluctuations in the MAP during changeover in 
any given environmental condition used.
COnClusIOns
Our studies highlight that a commonly used SOP for delivery of 
dopamine in hypotensive care of neonates in intensive care units 
is subjective to rapid fluctuations in the MAP following change-
over of dopamine infusions. Using a simulated environment, 
these alterations in the MAP correlated with a loss in the dopa-
mine concentration as a result of degradation over 24 hours. By 
adopting a new SOP where dopamine infusions were prepared 
30 min prior to administration and changed every 12 hours, both 
a reduction in rapid fluctuations in MAP and loss in the dopa-
mine concentration due to degradation were minimised. Our 
new SOP has major implications to remove unwanted risk to 
neonates and should be implemented by clinical staff who are 
currently changing infusions of dopamine every 24 hours.
Twitter @bhavikanilpatel
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